Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery

Eman Zmaily Dahmash,Nour Radwan Achkar,Dalia Khalil Ali,Qais Jarrar,Affiong Iyire,Shereen M. Assaf,Hamad Alyami
DOI: https://doi.org/10.1038/s41598-024-59588-1
IF: 4.6
2024-04-30
Scientific Reports
Abstract:Fixed dose combinations (FDCs) incorporating two or three medicines in a single inhaler have been created to enhance patient compliance and hence clinical outcomes. However, the development of dry powder inhalers (DPIs), particularly for FDCs, faces challenges pertinent to formulation uniformity and reproducibility. Therefore, this project aimed to employ nanotechnology to develop a FDC of DPIs for market-leading medicines—fluticasone propionate (FP) and salmeterol xinafoate (SAL)—for asthma management. Nanoaggregates were prepared using a novel biocompatible and biodegradable poly(ester amide) based on the amino acid tyrosine, utilising a one-step interfacial polymerisation process. The produced tyrosine poly (ester amide) drug-loaded nanoparticles were evaluated for content uniformity, PSA, FTIR, TEM, DSC, XRD and aerodynamic performance (in vitro and in vivo). The optimised formulation demonstrated high entrapment efficiency– > 90%. The aerodynamic performance in terms of the emitted dose, fine particle fraction and respirable dose was superior to the carrier-based marketed product. In-vivo studies showed that FP (above the marketed formulation) and SAL reached the lungs of mice in a reproducible manner. These results highlight the superiority of novel FDC FP/SAL nanoparticles prepared via a one-step process, which can be used as a cost-effective and efficient method to alleviate the burden of asthma.
multidisciplinary sciences
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to develop a new fixed - dose combination (FDC) dry powder inhaler (DPI) for asthma management. Specifically, the researchers hope to prepare nanoparticles based on Tyrosine Poly(Ester Amide) (Tyr - PEA) through nanotechnology to improve the efficiency of targeted lung drug delivery and clinical efficacy. ### Research Background and Problems 1. **Existing Challenges**: - The development of dry powder inhalers (DPIs), especially for fixed - dose combinations (FDCs), faces challenges in formulation uniformity and reproducibility. - The existing DPIs on the market have deficiencies in dose control, targeting, and bioavailability of drug delivery. 2. **Research Objectives**: - Develop nanoparticles based on a new biocompatible and degradable polyesteramide (Tyr - PEA) for loading asthma treatment drugs - Fluticasone Propionate (FP) and Salmeterol Xinafoate (SAL). - Improve the targeted lung drug - delivery performance of drugs through nanotechnology and increase the drug encapsulation efficiency and aerodynamic performance. ### Main Research Contents 1. **Synthesis of Nanoparticles**: - Use interfacial polymerization to prepare Tyr - PEA - based nanoparticles. - Simultaneously achieve polymer synthesis and drug encapsulation in one - step. 2. **Performance Evaluation**: - **Encapsulation Efficiency**: The optimized formula shows a high encapsulation efficiency of over 90%. - **Aerodynamic Performance**: Evaluate the aerodynamic performance of nanoparticles through in vitro and in vivo experiments, including emitted dose, fine particle fraction, and inhalable dose. - **In Vivo Studies**: The results show that FP and SAL can reach the lungs of mice in a reproducible manner and are more effective than commercially available products. ### Significance - **Clinical Application**: The preparation method of the new FDC FP/SAL nanoparticles is cost - effective and efficient and can reduce the burden on asthma patients. - **Technical Advantages**: Nanoparticle technology shows significant advantages in improving drug - delivery efficiency, reducing dosage, enhancing dissolution, and improving lung retention. ### Conclusion This study has successfully developed nanoparticles based on tyrosine polyesteramide for fixed - dose - combination dry powder inhalers, significantly improving the targeted lung - drug - delivery performance and clinical efficacy. This achievement provides a new and effective means for asthma management.